Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ · Healthcare
Arcturus Therapeutics Holdings Inc. EBITDA 2018–2025
Arcturus Therapeutics Holdings Inc. annual/quarterly ebitda history and growth rate from 2018 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Arcturus Therapeutics Holdings Inc. ebitda for the quarter ending March 31, 2026 was -28.3 M, a 76.43% increase year-over-year.
- Arcturus Therapeutics Holdings Inc. ebitda for the twelve months ending March 31, 2026 was -70.8 M, a 9.30% decrease year-over-year.
- Arcturus Therapeutics Holdings Inc. annual ebitda for 2025 was -73.2 M, a 20.50% decrease from 2024.
- Arcturus Therapeutics Holdings Inc. annual ebitda for 2024 was -92.1 M, a 22.43% increase from 2023.
- Arcturus Therapeutics Holdings Inc. annual ebitda for 2023 was -75.2 M, a 649.10% decrease from 2022.
- Arcturus Therapeutics Holdings Inc. annual ebitda for 2022 was 13.7 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Arcturus Therapeutics Holdings Inc. EBITDA — FAQ
Arcturus Therapeutics Holdings Inc. (ARCT) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ARCT's ebitda history?
The chart and table above show Arcturus Therapeutics Holdings Inc.'s ebitda by year and by quarter, including the growth rate.